January 9, 2026
Clinical Updates
Cablivi® (caplacizumab-yhdp) – Expanded indication
December 23, 2025 - The FDA approved Sanofi’s Cablivi (caplacizumab-yhdp), for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Drug Approvals
Nereus™ (tradipitant) – New drug approval
December 30, 2025 - Vanda announced the FDA approval of Nereus (tradipitant), for the prevention of vomiting induced by motion in adults.
Drug Recalls - Availability
Eli Lilly – Discontinuation of Omvoh® (mirikizumab-mrkz) 100 mg/mL subcutaneous injection
December 22, 2025 - Eli Lilly announced a business decision to discontinue Omvoh (mirikizumab-mrkz) 100 mg/mL subcutaneous injection. Omvoh is not being discontinued for reasons of safety or effectiveness.